{
    "id": 11023,
    "fullName": "HIP1 - ALK",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HIP1-ALK results from the fusion of HIP1 and ALK (PMID: 24496003). HIP1-ALK has been identified in non-small cell lung cancer (PMID: 25393796) and lung adenocarcinoma (PMID: 24496003), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 5028,
                    "pubMedId": 25393796,
                    "title": "Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25393796"
                },
                {
                    "id": 3565,
                    "pubMedId": 24496003,
                    "title": "HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496003"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3092,
        "geneSymbol": "HIP1",
        "terms": [
            "HIP1",
            "HIP-I",
            "ILWEQ",
            "SHON",
            "SHONbeta",
            "SHONgamma"
        ]
    },
    "variant": "HIP1 - ALK",
    "createDate": "08/27/2015",
    "updateDate": "01/29/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 5600,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with HIP1-ALK positive lung adenocarcinoma had a complete response to Alecensa (alectinib) lasting 2 months (PMID: 25393796).",
            "molecularProfile": {
                "id": 11061,
                "profileName": "HIP1 - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5028,
                    "pubMedId": 25393796,
                    "title": "Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25393796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16908,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WX-0593 inhibited Alk downstream signaling and tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring HIP1-ALK (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).",
            "molecularProfile": {
                "id": 11061,
                "profileName": "HIP1 - ALK"
            },
            "therapy": {
                "id": 8236,
                "therapyName": "WX-0593",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15046,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of WX-0593, a potent orally active ALK inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/4794.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3006,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited tumor growth in a patient-derived xenograft model of squamous cell lung carcinoma harboring a HIP1-ALK fusion (PMID: 24496003).",
            "molecularProfile": {
                "id": 11061,
                "profileName": "HIP1 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3565,
                    "pubMedId": 24496003,
                    "title": "HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24496003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5743,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with HIP1-ALK positive lung adenocarcinoma demonstrated a durable partial response when treated with Xalkori (crizotinib) (PMID: 25393796).",
            "molecularProfile": {
                "id": 11061,
                "profileName": "HIP1 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5028,
                    "pubMedId": 25393796,
                    "title": "Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25393796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5742,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with HIP1-ALK positive lung adenocarcinoma developed resistance to Alecensa (alectinib) after the emergence of ALK I1171N (PMID: 25393796).",
            "molecularProfile": {
                "id": 21549,
                "profileName": "HIP1 - ALK ALK I1171N"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5028,
                    "pubMedId": 25393796,
                    "title": "Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25393796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11061,
            "profileName": "HIP1 - ALK",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21549,
            "profileName": "HIP1 - ALK ALK I1171N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}